Press releases

Release issued 15th January 2007

York, UK, 15 Jan 2006 - Pharmaceutical research and development in China is being constantly accelerated by successful clinical trials, a growing number of established R&D specialist companies and scientific technical expertise. The Chinese pharmaceutical market is currently worth around $US12 billion.

Launched today from Pharmalicensing is The Chinese Pharmaceutical Market: A strategic opportunity analysis; a report that explores the present state of the Chinese Pharmaceutical market and the many partnering opportunities available to companies wishing to take advantage of low labor costs, high quality clinical data and first class R&D facilities.   

Detailing the driving forces behind the pharma market and informing readers of the history and current state of the healthcare system along with effect of the Chinese macro-environment, the report provides a thorough view of how the pharmaceutical industry operates in China and describes the regulations and systems that potential partners must consider. Concluding with a round up of the Chinese companies actively involved in drug discovery, the report includes a breakdown of the market’s key players.

The Chinese government also plays an instrumental role in the pharmaceutical development of China. The introduction of WTO guidelines and protection for intellectual property rights has caused a shift in the company structures of China, forcing some to close business or enter into new collaborations.

For more information on ' China Pharmaceutical Market: A strategic opportunity analysis ' or other reports, go to store.pharmalicensing.com, or contact the reports team on tel: +44 1904 520460 or email: sales@pharmalicensing.com

Pharmalicensing Ltd (pharmalicensing.com), based in York, UK, is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry.

Contact: Johan Ohlsson, Strategic Analyst, Business Development (johan.ohlsson@pharmalicensing.com; Tel +44 1904 520491)

(20th May 2013) Pharmalicensing and Bionow sign strategic marketing and member benefit agreement

(5th January 2012) Innovaro Announces Successful Sale of the Waycool Portfolio of Patents by CUI Global, Inc.

(28th January 2010) New collaboration presents big opportunities for UK SMEs

(14th January 2010) UTEK Pharmalicensing.com Announces New Pricing Model: Pay-per-Click to Expand Listed Opportunities, Extend Reach and Remove Market Barriers

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.